CécileCouchoud REIN registry, Agence de la biomédecine, FranceFrance

Institution

Time	Session

3 p.m. 4 p.m.	Late Breaking Clinical Trials Session AlessiaFornoni Chairperson United States MichelleRheault Chairperson rheau002@umn.eduUniversity of MinnesotaUnited States Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict) PietroRavani Free Communication pravani@ucalgary.caUniversity of CalgaryCanada Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research ConsultantDenmark EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY DanaRizk Free Communication drizk@uabmc.eduUniversity of Alabama at BirminghamUnited States SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL JonathanBarratt Free Communication University of Leicester, Leicester, UKUnited Kingdom PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT CécileCouchoud Free Communication cecile.couchoud@biomedecine.frREIN registry, Agence de la biomédecine, FranceFrance Hall A

Time

Session

3 p.m.

4 p.m.

Late Breaking Clinical Trials Session

AlessiaFornoni Chairperson United States

MichelleRheault Chairperson rheau002@umn.eduUniversity of MinnesotaUnited States

Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict)

PietroRavani Free Communication pravani@ucalgary.caUniversity of CalgaryCanada
Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas

Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research ConsultantDenmark
EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY

DanaRizk Free Communication drizk@uabmc.eduUniversity of Alabama at BirminghamUnited States
SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL

JonathanBarratt Free Communication University of Leicester, Leicester, UKUnited Kingdom
PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT

CécileCouchoud Free Communication cecile.couchoud@biomedecine.frREIN registry, Agence de la biomédecine, FranceFrance

Hall A